ANVS Falls Nearly 48% as $21 Million Offering Puts Dilution in Focus
Annovis Bio's share-and-warrant offering raises funding while adding ownership pressure, against the backdrop of a recent NYSE compliance notice.
Read the story
Annovis Bio's share-and-warrant offering raises funding while adding ownership pressure, against the backdrop of a recent NYSE compliance notice.
Read the story